Septerna
No price chart data available for 1D timeframe.
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Septerna, Inc., a clinical-stage biotechnology company, discovers and develops G protein-coupled receptor (GPCR) oral small molecule products for the treatment of endocrinology, immunology and inflamm...
Latest News
5 days ago · seekingalpha.com
Septerna: The SEP-479 Readout Could Unlock Further UpsideSepterna, Inc. is positioned for near-term value creation, with SEP-479 as the primary catalyst and a strong cash runway into 2029. SEP-479's Phase 1 readout in 1Q27 could provide the first meaningful clinical validation of SEPN's GPCR platform, with safety and key biomarker data in focus. SEP-204 is expected to enter Phase 1 in 1Q27, offering a differentiated oral approach for Graves' disease and thyroid eye disease with promising preclinical selectivity.
7 days ago · zacks.com
Septerna, Inc. (SEPN) Reports Q3 Loss, Lags Revenue EstimatesSepterna, Inc. (SEPN) came out with a quarterly loss of $0.57 per share versus the Zacks Consensus Estimate of a loss of $0.55. This compares to a loss of $0.09 per share a year ago.
13 days ago · globenewswire.com
Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual MeetingPotent, selective TSHR NAM with pre-clinical activity demonstrated across biochemical, thyroid and ocular endpoints Favorable PK profile anticipated to support once-daily oral dosing in humans Phase 1 clinical trial initiation planned for the first quarter of 2027 SOUTH SAN FRANCISCO, Calif., Nov. 04, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the selection of SEP-204 as its potential first-in-class development candidate for the treatment of Graves' disease and thyroid eye disease (TED) and reported initial preclinical data ahead of a poster presentation at the 2026 American Thyroid Association (ATA) Annual Meeting on November 5.
14 days ago · globenewswire.com
Septerna to Participate in Upcoming Investor ConferencesSOUTH SAN FRANCISCO, Calif., Nov. 03, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced that management will participate in the following investor conferences before the end of 2026: Guggenheim 3rd Annual Healthcare Innovation Conference – Boston Fireside chat on Tuesday, November 10, 2026, at 10:00 a.m.
3 months ago · globenewswire.com
Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical OfficerSOUTH SAN FRANCISCO, Calif., Aug. 25, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, today announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni is a physician-scientist and accomplished biopharmaceutical executive with more than 25 years of experience leading research, development, regulatory, and medical affairs organizations.
3 months ago · zacks.com
Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue EstimatesSepterna, Inc. (SEPN) came out with a quarterly loss of $0.29 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to a loss of $0.56 per share a year ago.
5 months ago · fool.com
Is Septerna a Stock to Sell After an Insider Let Go of 15,000 Shares?15,000 shares were exercised and sold for a total of ~$533,000 on June 22, 2026, at a weighted average price of around $35.51 per share. This transaction impacted 13.46% of Long's direct Common Stock holdings, reducing his position to 96,412 shares.
6 months ago · zacks.com
Septerna, Inc. (SEPN) Reports Q1 Loss, Tops Revenue EstimatesSepterna, Inc. (SEPN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.51. This compares to a loss of $0.49 per share a year ago.
6 months ago · globenewswire.com
Septerna Highlights Business Progress and Reports First Quarter 2026 Financial ResultsCompelling Phase 1 Data for SEP-631 (MRGPRX2 NAM) in Healthy Volunteers Support Phase 2b Development, Initially in Chronic Spontaneous Urticaria (CSU) in Second Half of 2026
7 months ago · globenewswire.com
Septerna to Present at Bank of America Securities Health Care ConferenceSOUTH SAN FRANCISCO, Calif., May 05, 2026 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) drug discovery, announced that Jeffrey Finer, M.D.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove SEPN